7 results about "Free cholesterol" patented technology

The invention relates to a high-coverage quantitative analysis method of lipidome and a quantitative kit, the method adopts a mobile phase A and a mobile phase B with different pH values for elution, the pH value of the mobile phase B is 2.5-5, and the pH value of the mobile phase A is 2.5-3.0. According to the method, good separation of acid-sensitive lipid compounds such as PA, S1P and PS can be realized, ionization inhibition of lipid compounds such as free fatty acid and free cholesterol can be reduced, and the quantitative sensitivity of the lipid compounds can be improved. According to the method, 104 lipid subclasses can be covered, 2375 lipid compounds can be quantified, and the number of the lipid compounds is more than two times that of the lipid compounds in the existing lipidomics quantitative method. The lipidome quantitative kit can be used for quantitatively analyzing lipidomes of seven biological samples such as plasma, urine, cells, liver and excrement of human or animal sources as well as escherichia coli and arabidopsis rosette leaves, and can meet quantitative analysis requirements of lipidomes in different biological samples.

The invention belongs to the technical field of molecular biology and medicine, and particularly relates to application of lncRNA TUG1 serving as a target spot to preparation of a medicine for treating metabolism-related fatty liver diseases. According to the application disclosed by the invention, it is found that lncRNA TUG1 can be knocked down in a targeted manner by transfecting siRNA in human hepatoma carcinoma cells HepG2, so that the expression of the lncRNA TUG1 is reduced, and the contents of total cholesterol, free cholesterol and triglyceride are remarkably reduced; meanwhile, the mouse hepatoma carcinoma cell Hepa1-6 is transfected with siRNA to knock down lncRNA TUG1, so that the expression of the mouse hepatoma carcinoma cell Hepa1-6 is reduced. Besides, an MAFLD animal model is established, and it is found that compared with a control group, the expression of lncRNA TUG1 in the mouse liver of the model group is remarkably improved. The results indicate that the lncRNA TUG1 possibly becomes a new target for developing MAFLD related drugs, and it is clear that the lncRNA TUG1 affects generation of fat and cholesterol to achieve treatment intervention on MAFLD.

The invention discloses a blood chyle degree detection reference and a preparation method thereof. The reference comprises the following components: triglyceride, cholesteryl ester, free cholesterol, phosphatidylcholine, bovine serum albumin, a buffer solution and an auxiliary agent. The blood chyle degree detection reference product provided by the invention can be stably stored, is low in cost, can be used for instrument calibration, can be used for judging and grading clinical plasma chyle degree and the like, and can unify detection standards and eliminate artificial interference; based on the blood chyle degree detection reference product provided by the invention, detection can be realized by utilizing image gray calculation, and compared with manual visual inspection, the detection accuracy is greatly improved.

The application discloses application of a genipin in preparation of a medicine for treating cholangiocarcinoma, and belongs to the field of biological medicines. The cell experiment result shows that the genipin can inhibit cholangiocarcinoma cell proliferation, migration and invasion capacity. The application proves that the genipin can effectively relieve occurrence and development of cholangiocarcinoma by constructing an in-situ cholangiocarcinoma animal model, observing mouse liver weight and liver coefficient, and observing liver tissue pathological HE staining. The application also verifies that the genipin can directly combine with PCSK9 by using proteomics, Western blot, molecular docking technology, surface plasmon resonance experiment and detection of cholesterol and lipid raft level, promotes accumulation of free cholesterol in tumor cells, disturbs cholesterol homeostasis and changes lipid raft structure, thereby playing an anti-tumor role. The application first finds that the genipin has specific effects in inhibiting cholangiocarcinoma progression, and is non-toxic and has no side effects, and can be used alone or in combination as a means for preventing and treating cholangiocarcinoma for development.

The invention belongs to the field of biological medicines, and particularly relates to application of riboadenosine in preparation of medicines for treating fatty liver and relieving obesity. Cell experiments, organoid experiments and animal experiments find and confirm that the riboadenosine can reduce lipid accumulation and reduce body weight so as to relieve obesity, and can prevent and improve metabolic diseases related to obesity; particularly, liboadenosine is found to be capable of inhibiting synthesis of fatty acid and cholesterol in liver cells, reducing levels of fatty acid, triglyceride and free cholesterol, improving liver functions, reducing liver injury and preventing and treating metabolic fatty liver.

The present application belongs to the field of biological medicine, and particularly relates to the use of ribo-adenosine in the preparation of a medicine for treating fatty liver and reducing obesity. The present application finds and confirms, through cell experiments, organoid experiments and animal experiments, that ribo-adenosine can reduce lipid accumulation, reduce body weight and thus reduce obesity, and can prevent and improve metabolic diseases related to obesity; in particular, the present application finds that ribo-adenosine can inhibit the synthesis of fatty acids and cholesterol in liver cells, reduce the levels of fatty acids, triglycerides and free cholesterol, improve liver function, reduce liver damage, and play a preventive and therapeutic role in metabolic fatty liver.

The invention provides construction and application of an asthma risk prediction model based on lifestyle-related metabolites, and provides application of a reagent for detecting the content of multiple metabolites in preparation of a reagent or a kit for predicting the risk of late-onset asthma. The metabolite content is the following nine metabolite contents: unsaturation degree, tyrosine, albumin, glycoprotein acetylation, free cholesterol in large low-density lipoprotein, extra-large high-density lipoprotein particle concentration, cholesterol in extra-large high-density lipoprotein, free cholesterol in extra-large high-density lipoprotein and phospholipid in small high-density lipoprotein. The prediction model combines the nine serum metabolites, clinical characteristics and lifestyle scoring, the prediction accuracy is high, the AUC can reach 0.837, and the prediction method is obviously superior to a prediction method only depending on the clinical characteristics (AUC = 0.644) and lifestyle factors (AUC = 0.743).